This table shows the probability of having each of the four pathologic stages of prostate cancer based on Gleason score, clinical stage and a PSA level greater than 20.0 ng/ml.
Examples
|
PSA >
20.0 ng/ml
|
Probability
of Pathologic Stage (%)
|
|
Clinical
Stage
|
||||||||
|
Gleason
score
|
Pathologic stage |
T1a |
T1b
|
T1c |
T2a |
T2b |
T2c
|
T3a |
|
2-4
|
Organ-confined
disease Established
capsular penetration |
|
|
|
|
|
|
|
|
5
|
Organ-confined
disease Established capsular penetration Seminal vesicle involvement Lymph node involvement |
|
23 |
40 |
26 |
17 |
19 |
8 |
|
6
|
Organ-confined
disease Established capsular penetration Seminal vesicle involvement Lymph node involvement |
|
17 |
35 |
22 |
13 |
15 |
6 |
|
7
|
Organ-confined
disease Established capsular penetration Seminal vesicle involvement Lymph node involvement |
|
|
18 |
10 |
5 |
6 |
2 |
|
8-10
|
Organ-confined
disease Established capsular penetration Seminal vesicle involvement Lymph node involvement |
|
3 |
10 |
5 |
3 |
3 |
1 |
Reference: Partin AW, Kattan
MW, Subong EN, Walsh PC, et al. Combination of prostate-specific
antigen, clinical stage and Gleason score to predict pathological
stage of localized prostate cancer: A multi-institutional
update. JAMA 1997;277:1445-1451. Copyrighted 1997,
American Medical Association. Reprinted with permission.
About This Web Site
|
Give Us Your Feedback
|
Privacy Statement
|
Disclaimer
|
Site Statistics
|
Informatics Web Resources
©
UPMC, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
412-647-2811
|
PCI-INFO@upmc.edu
|
Designed and maintained by the Department of Biomedical Informatics
Send questions and comments to UPCIwebupdates@upmc.edu
